Acadia Pharmaceuticals Inc. is rated a Buy for its steady NUPLAZID/DAYBUE franchises & pipeline-driven upside potential. Read more on ACAD stock here.
In its latest PFDD installment, the FDA offers a detailed roadmap for sponsors seeking to design, adapt, or validate COAs that accurately ...
Singapore is placing a SG$200 million bet on content as a global branding and commercial engine, with the launch of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback